Lundbeck news from FiercePharma
NewsLundbeck poaches CEO from Wyeth ranks
Wanted: CEO who can find a new "cash cow" to push a Danish drugmaker past impending patent expirations. Found: Ulf Wiinberg, lately of Wyeth, to take over Lundbeck. Soon to be ex-president Read more...
ALSO NOTED: Thai FDA chief quits after one week; Congress asks FDA to nuke self-labeling rule
> In the midst of a controversy over patent-busting compulsory licenses, Thailand's new Food and Drug Administration chief quit after one week on the job. Read more...
Lexapro, Namenda boost Forest
Who does Forest Labs appreciate? Lexapro and Namenda, to name two. The two drugs helped boost the drug maker's fiscal third-quarter net by 21 percent to $301 million, or 96 cents a share. Revenue was Read more...
ALSO NOTED: Caraco gets FDA nod for GSK seizure drug; Mylan prices offering of stock;
> Caraco Pharmaceutical got tentative FDA approval for its copycat form of GlaxoSmithKline's Lamictal, a remedy for seizures and bipolar episodes that sold some $1.89 billion in the 12 months Read more...
Forest Labs gets Lexapro protection
How does Forest Labs spell relief? P-A-T-E-N-T. A federal court has validated the company's Lexapro protection, safeguarding that blockbuster antidepressant and antianxiety drug through 2012. The Read more...
| Press ReleasesPRESS RELEASE: Lu AA21004 Shows Highly Significant Results in Clinical Phase II Trial Lu AA21004 Shows Highly Significant Results in Clinical Phase II Trial COPENHAGEN, Oct. 2, 2007-H. Lundbeck A/S today announced positive headline results from a newly unblinded proof of concept Read more... |
Get more Lundbeck coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets